Guttate Psoriasis clinical trials at UCSF

1 research study open to eligible people

Showing trials for

  • Guselkumab Immunogenetics

    open to eligible people ages 18 years and up

    This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.

    San Francisco, California

Our lead scientists for Guttate Psoriasis medical studies include .

Last updated: